Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343881 | 1.00 | ADORA3 (0.46) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| SCHEMBL20268268 | 1.00 | ADORA3 (0.46) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL298755 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL15804 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL4110068 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL6748954 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL12763613 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL20138477 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL2229394 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL330178 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712982-A1 | OLIGONUCLEOTIDES FOR DGAT2, FASN, OPN, AND NOX4 MODULATIONS | University of Massachusetts (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260035699-A1 | OLIGONUCLEOTIDES FOR PRNP MODULATION | UNIV MASSACHUSETTS (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260028381-A1 | SYSTEMS AND METHODS FOR PROMOTING TRANS-SPLICING | TACIT THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4684019-A2 | DENDRITIC CONJUGATES FOR THE BRAIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | University of Massachusetts (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12534724-B2 | Synthetic oligonucleotides having regions of block and cluster modifications | UNIVERSITY OF MASSACHUSETTS (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260015614-A1 | BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY | UNIV MASSACHUSETTS (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4676443-A1 | DENDRITIC CONJUGATES FOR THE SKIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | University of Massachusetts (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676496-A1 | TOPICAL DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | University of Massachusetts (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250354148-A1 | DUAL-ACTING siRNA BASED MODULATION OF C9orf72 | UNIV MASSACHUSETTS (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025227122-A1 | ADIPOSE-SELECTIVE BRANCHED RNA COMPOUNDS | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2009143345-A2 | NUCLEIC ACID SILENCING AGENT-PROTEIN CONJUGATES AND USE THEREOF FOR TREATING HCV-RELATED DISORDERS | UNIVERSITY OF MASSACHUSETTS (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090186410-A1 | RNA SILENCING COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009085215-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1994182-A2 | DEGENERATE NUCLEOBASE ANALOGS | Siemens Healthcare Diagnostics Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070259827-A1 | Compositions and methods for enhancing discriminatory RNA interference | UNIVERSITY OF MASSACHUSETTS (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007106690-A2 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007087451-A2 | COMPOSITIONS AND METHODS FOR ENHANCING DISCRIMINATORY RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015614-A1 | BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY | FABP3, CPT1B, FABP2 | ADORA3 3264/4885ADORA2A 4635/4885SMN1; SMN2 616/4885 |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | DTYMK, UNG, TPR | ADORA3 1671/4885ADORA2A 2400/4885SMN1; SMN2 2133/4885 |
| US-20260028381-A1 | SYSTEMS AND METHODS FOR PROMOTING TRANS-SPLICING | UPF1, RBM3, RBM17 | ADORA3 3560/4885ADORA2A 4527/4885SMN1; SMN2 208/4885 |
| US-20260035699-A1 | OLIGONUCLEOTIDES FOR PRNP MODULATION | PRNP, METTL16, UPF1 | ADORA3 388/4885ADORA2A 690/4885SMN1; SMN2 40/4885 |
| US-12534724-B2 | Synthetic oligonucleotides having regions of block and cluster modifications | NSUN2, NSUN3, NOP2 | ADORA3 814/4885ADORA2A 1242/4885SMN1; SMN2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.